La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

Identifieur interne : 000917 ( Main/Exploration ); précédent : 000916; suivant : 000918

Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

Auteurs : Calvin C. Willhite [Canada] ; Nataliya A. Karyakina [Canada] ; Robert A. Yokel [États-Unis] ; Nagarajkumar Yenugadhati [Canada] ; Thomas M. Wisniewski [États-Unis] ; Ian M. F. Arnold [Canada] ; Franco Momoli [Canada] ; Daniel Krewski [Canada]

Source :

RBID : PMC:4997813

Abstract

Aluminum (Al) is a ubiquitous substance encountered both naturally (as the third most abundant element) and intentionally (used in water, foods, pharmaceuticals, and vaccines); it is also present in ambient and occupational airborne particulates. Existing data underscore the importance of Al physical and chemical forms in relation to its uptake, accumulation, and systemic bioavailability. The present review represents a systematic examination of the peer-reviewed literature on the adverse health effects of Al materials published since a previous critical evaluation compiled by Krewski et al. (2007).

Challenges encountered in carrying out the present review reflected the experimental use of different physical and chemical Al forms, different routes of administration, and different target organs in relation to the magnitude, frequency, and duration of exposure. Wide variations in diet can result in Al intakes that are often higher than the World Health Organization provisional tolerable weekly intake (PTWI), which is based on studies with Al citrate. Comparing daily dietary Al exposures on the basis of “total Al” assumes that gastrointestinal bioavailability for all dietary Al forms is equivalent to that for Al citrate, an approach that requires validation. Current occupational exposure limits (OELs) for identical Al substances vary as much as 15-fold.

The toxicity of different Al forms depends in large measure on their physical behavior and relative solubility in water. The toxicity of soluble Al forms depends upon the delivered dose of Al+3 to target tissues. Trivalent Al reacts with water to produce bidentate superoxide coordination spheres [Al(O2)(H2O4)+2 and Al(H2O)6+3] that after complexation with O2•−, generate Al superoxides [Al(O2)](H2O5)]+2. Semireduced AlO2 radicals deplete mitochondrial Fe and promote generation of H2O2, O2•− and OH. Thus, it is the Al+3-induced formation of oxygen radicals that accounts for the oxidative damage that leads to intrinsic apoptosis. In contrast, the toxicity of the insoluble Al oxides depends primarily on their behavior as particulates.

Aluminum has been held responsible for human morbidity and mortality, but there is no consistent and convincing evidence to associate the Al found in food and drinking water at the doses and chemical forms presently consumed by people living in North America and Western Europe with increased risk for Alzheimer’s disease (AD). Neither is there clear evidence to show use of Al-containing underarm antiperspirants or cosmetics increases the risk of AD or breast cancer. Metallic Al, its oxides, and common Al salts have not been shown to be either genotoxic or carcinogenic. Aluminum exposures during neonatal and pediatric parenteral nutrition (PN) can impair bone mineralization and delay neurological development. Adverse effects to vaccines with Al adjuvants have occurred; however, recent controlled trials found that the immunologic response to certain vaccines with Al adjuvants was no greater, and in some cases less than, that after identical vaccination without Al adjuvants.

The scientific literature on the adverse health effects of Al is extensive. Health risk assessments for Al must take into account individual co-factors (e.g., age, renal function, diet, gastric pH). Conclusions from the current review point to the need for refinement of the PTWI, reduction of Al contamination in PN solutions, justification for routine addition of Al to vaccines, and harmonization of OELs for Al substances.


Url:
DOI: 10.3109/10408444.2014.934439
PubMed: 25233067
PubMed Central: 4997813


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts</title>
<author>
<name sortKey="Willhite, Calvin C" sort="Willhite, Calvin C" uniqKey="Willhite C" first="Calvin C." last="Willhite">Calvin C. Willhite</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Risk Sciences International, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Risk Sciences International, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Karyakina, Nataliya A" sort="Karyakina, Nataliya A" uniqKey="Karyakina N" first="Nataliya A." last="Karyakina">Nataliya A. Karyakina</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Risk Sciences International, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Risk Sciences International, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Yokel, Robert A" sort="Yokel, Robert A" uniqKey="Yokel R" first="Robert A." last="Yokel">Robert A. Yokel</name>
<affiliation wicri:level="2">
<nlm:aff id="A3">Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky</wicri:regionArea>
<placeName>
<region type="state">Kentucky</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yenugadhati, Nagarajkumar" sort="Yenugadhati, Nagarajkumar" uniqKey="Yenugadhati N" first="Nagarajkumar" last="Yenugadhati">Nagarajkumar Yenugadhati</name>
<affiliation wicri:level="1">
<nlm:aff id="A2">McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wisniewski, Thomas M" sort="Wisniewski, Thomas M" uniqKey="Wisniewski T" first="Thomas M." last="Wisniewski">Thomas M. Wisniewski</name>
<affiliation wicri:level="2">
<nlm:aff id="A4">Departments of Neurology, Psychiatry and Pathology, New York University School of Medicine, New York City, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Psychiatry and Pathology, New York University School of Medicine, New York City, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Arnold, Ian M F" sort="Arnold, Ian M F" uniqKey="Arnold I" first="Ian M. F." last="Arnold">Ian M. F. Arnold</name>
<affiliation wicri:level="4">
<nlm:aff id="A5">Occupational Health Program, Faculty of Medicine, McGill University, Montreal, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Occupational Health Program, Faculty of Medicine, McGill University, Montreal, QC</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Momoli, Franco" sort="Momoli, Franco" uniqKey="Momoli F" first="Franco" last="Momoli">Franco Momoli</name>
<affiliation wicri:level="1">
<nlm:aff id="A6">Ottawa Hospital Research Institute, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ottawa Hospital Research Institute, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A7">Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A8">Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Risk Sciences International, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Risk Sciences International, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A7">Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">25233067</idno>
<idno type="pmc">4997813</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997813</idno>
<idno type="RBID">PMC:4997813</idno>
<idno type="doi">10.3109/10408444.2014.934439</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000857</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000857</idno>
<idno type="wicri:Area/Pmc/Curation">000857</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000857</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000406</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000406</idno>
<idno type="wicri:Area/Ncbi/Merge">001910</idno>
<idno type="wicri:Area/Ncbi/Curation">001910</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001910</idno>
<idno type="wicri:doubleKey">1040-8444:2014:Willhite C:systematic:review:of</idno>
<idno type="wicri:Area/Main/Merge">000919</idno>
<idno type="wicri:Area/Main/Curation">000917</idno>
<idno type="wicri:Area/Main/Exploration">000917</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts</title>
<author>
<name sortKey="Willhite, Calvin C" sort="Willhite, Calvin C" uniqKey="Willhite C" first="Calvin C." last="Willhite">Calvin C. Willhite</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Risk Sciences International, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Risk Sciences International, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Karyakina, Nataliya A" sort="Karyakina, Nataliya A" uniqKey="Karyakina N" first="Nataliya A." last="Karyakina">Nataliya A. Karyakina</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Risk Sciences International, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Risk Sciences International, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Yokel, Robert A" sort="Yokel, Robert A" uniqKey="Yokel R" first="Robert A." last="Yokel">Robert A. Yokel</name>
<affiliation wicri:level="2">
<nlm:aff id="A3">Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky</wicri:regionArea>
<placeName>
<region type="state">Kentucky</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yenugadhati, Nagarajkumar" sort="Yenugadhati, Nagarajkumar" uniqKey="Yenugadhati N" first="Nagarajkumar" last="Yenugadhati">Nagarajkumar Yenugadhati</name>
<affiliation wicri:level="1">
<nlm:aff id="A2">McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wisniewski, Thomas M" sort="Wisniewski, Thomas M" uniqKey="Wisniewski T" first="Thomas M." last="Wisniewski">Thomas M. Wisniewski</name>
<affiliation wicri:level="2">
<nlm:aff id="A4">Departments of Neurology, Psychiatry and Pathology, New York University School of Medicine, New York City, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Psychiatry and Pathology, New York University School of Medicine, New York City, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Arnold, Ian M F" sort="Arnold, Ian M F" uniqKey="Arnold I" first="Ian M. F." last="Arnold">Ian M. F. Arnold</name>
<affiliation wicri:level="4">
<nlm:aff id="A5">Occupational Health Program, Faculty of Medicine, McGill University, Montreal, QC, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Occupational Health Program, Faculty of Medicine, McGill University, Montreal, QC</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Momoli, Franco" sort="Momoli, Franco" uniqKey="Momoli F" first="Franco" last="Momoli">Franco Momoli</name>
<affiliation wicri:level="1">
<nlm:aff id="A6">Ottawa Hospital Research Institute, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ottawa Hospital Research Institute, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A7">Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A8">Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Risk Sciences International, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Risk Sciences International, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>McLaughlin Centre for Population Health Risk Assessment, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A7">Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Critical reviews in toxicology</title>
<idno type="ISSN">1040-8444</idno>
<idno type="eISSN">1547-6898</idno>
<imprint>
<date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p id="P1">Aluminum (Al) is a ubiquitous substance encountered both naturally (as the third most abundant element) and intentionally (used in water, foods, pharmaceuticals, and vaccines); it is also present in ambient and occupational airborne particulates. Existing data underscore the importance of Al physical and chemical forms in relation to its uptake, accumulation, and systemic bioavailability. The present review represents a systematic examination of the peer-reviewed literature on the adverse health effects of Al materials published since a previous critical evaluation compiled by
<xref rid="R356" ref-type="bibr">Krewski et al. (2007)</xref>
.</p>
<p id="P2">Challenges encountered in carrying out the present review reflected the experimental use of different physical and chemical Al forms, different routes of administration, and different target organs in relation to the magnitude, frequency, and duration of exposure. Wide variations in diet can result in Al intakes that are often higher than the World Health Organization provisional tolerable weekly intake (PTWI), which is based on studies with Al citrate. Comparing daily dietary Al exposures on the basis of “total Al” assumes that gastrointestinal bioavailability for all dietary Al forms is equivalent to that for Al citrate, an approach that requires validation. Current occupational exposure limits (OELs) for identical Al substances vary as much as 15-fold.</p>
<p id="P3">The toxicity of different Al forms depends in large measure on their physical behavior and relative solubility in water. The toxicity of soluble Al forms depends upon the delivered dose of Al
<sup>+3</sup>
to target tissues. Trivalent Al reacts with water to produce bidentate superoxide coordination spheres [Al(O
<sub>2</sub>
)(H
<sub>2</sub>
O
<sub>4</sub>
)
<sup>+2</sup>
and Al(H
<sub>2</sub>
O)
<sub>6</sub>
<sup>+3</sup>
] that after complexation with O
<sub>2</sub>
<sup>•−</sup>
, generate Al superoxides [Al(O
<sub>2</sub>
<sup></sup>
)](H
<sub>2</sub>
O
<sub>5</sub>
)]
<sup>+2</sup>
. Semireduced AlO
<sub>2</sub>
<sup></sup>
radicals deplete mitochondrial Fe and promote generation of H
<sub>2</sub>
O
<sub>2</sub>
, O
<sub>2</sub>
<sup>•−</sup>
and OH
<sup></sup>
. Thus, it is the Al
<sup>+3</sup>
-induced formation of oxygen radicals that accounts for the oxidative damage that leads to intrinsic apoptosis. In contrast, the toxicity of the insoluble Al oxides depends primarily on their behavior as particulates.</p>
<p id="P4">Aluminum has been held responsible for human morbidity and mortality, but there is no consistent and convincing evidence to associate the Al found in food and drinking water at the doses and chemical forms presently consumed by people living in North America and Western Europe with increased risk for Alzheimer’s disease (AD). Neither is there clear evidence to show use of Al-containing underarm antiperspirants or cosmetics increases the risk of AD or breast cancer. Metallic Al, its oxides, and common Al salts have not been shown to be either genotoxic or carcinogenic. Aluminum exposures during neonatal and pediatric parenteral nutrition (PN) can impair bone mineralization and delay neurological development. Adverse effects to vaccines with Al adjuvants have occurred; however, recent controlled trials found that the immunologic response to certain vaccines with Al adjuvants was no greater, and in some cases less than, that after identical vaccination without Al adjuvants.</p>
<p id="P5">The scientific literature on the adverse health effects of Al is extensive. Health risk assessments for Al must take into account individual co-factors (e.g., age, renal function, diet, gastric pH). Conclusions from the current review point to the need for refinement of the PTWI, reduction of Al contamination in PN solutions, justification for routine addition of Al to vaccines, and harmonization of OELs for Al substances.</p>
</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
<li>États-Unis</li>
</country>
<region>
<li>Kentucky</li>
<li>Québec</li>
<li>État de New York</li>
</region>
<settlement>
<li>Montréal</li>
</settlement>
<orgName>
<li>Université McGill</li>
</orgName>
</list>
<tree>
<country name="Canada">
<noRegion>
<name sortKey="Willhite, Calvin C" sort="Willhite, Calvin C" uniqKey="Willhite C" first="Calvin C." last="Willhite">Calvin C. Willhite</name>
</noRegion>
<name sortKey="Arnold, Ian M F" sort="Arnold, Ian M F" uniqKey="Arnold I" first="Ian M. F." last="Arnold">Ian M. F. Arnold</name>
<name sortKey="Karyakina, Nataliya A" sort="Karyakina, Nataliya A" uniqKey="Karyakina N" first="Nataliya A." last="Karyakina">Nataliya A. Karyakina</name>
<name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name>
<name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name>
<name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name>
<name sortKey="Momoli, Franco" sort="Momoli, Franco" uniqKey="Momoli F" first="Franco" last="Momoli">Franco Momoli</name>
<name sortKey="Momoli, Franco" sort="Momoli, Franco" uniqKey="Momoli F" first="Franco" last="Momoli">Franco Momoli</name>
<name sortKey="Momoli, Franco" sort="Momoli, Franco" uniqKey="Momoli F" first="Franco" last="Momoli">Franco Momoli</name>
<name sortKey="Willhite, Calvin C" sort="Willhite, Calvin C" uniqKey="Willhite C" first="Calvin C." last="Willhite">Calvin C. Willhite</name>
<name sortKey="Yenugadhati, Nagarajkumar" sort="Yenugadhati, Nagarajkumar" uniqKey="Yenugadhati N" first="Nagarajkumar" last="Yenugadhati">Nagarajkumar Yenugadhati</name>
</country>
<country name="États-Unis">
<region name="Kentucky">
<name sortKey="Yokel, Robert A" sort="Yokel, Robert A" uniqKey="Yokel R" first="Robert A." last="Yokel">Robert A. Yokel</name>
</region>
<name sortKey="Wisniewski, Thomas M" sort="Wisniewski, Thomas M" uniqKey="Wisniewski T" first="Thomas M." last="Wisniewski">Thomas M. Wisniewski</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000917 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000917 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4997813
   |texte=   Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25233067" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022